Reported 2 months ago
Recent earnings reports from Eli Lilly and Novo Nordisk illustrate the fluctuating dynamics of the GLP-1 drug market. Novo Nordisk faced a revenue shortfall due to supply constraints on its Wegovy weight-loss drug, causing its stock to drop. In contrast, Eli Lilly exceeded sales expectations for its obesity and diabetes treatments, prompting a surge in its stock price. The competitive landscape is expected to broaden with new entrants and innovations, creating a multi-faceted race in the GLP-1 market, which remains a vital sector in the pharmaceutical industry.
Source: YAHOO